Who Is Not a Good Candidate for At-Home Ketamine Therapy?

Not everyone who is interested in ketamine should take it, and a responsible provider will tell you so. This article is a plain look at ketamine therapy eligibility: the ketamine contraindications and risk factors that can rule someone out, and why a clinical assessment comes before any prescription. At home, there is no clinician in the room to catch a problem as it develops, according to the FDA. That makes the screening done beforehand matter even more.

Quick answer: Who should not take ketamine comes down to a short list of ketamine contraindications, including aneurysmal vascular disease, a history of bleeding in the brain, and an allergy to ketamine. High blood pressure, active psychosis, pregnancy, and certain substance use histories can also rule someone out. A clinical assessment decides the rest, which is why screening comes first for at-home ketamine therapy.

What are the absolute ketamine contraindications?

Ketamine itself is not FDA approved for any psychiatric condition. The closest FDA-approved reference is Spravato, a nasal spray made from esketamine, one half of the ketamine molecule. It is a different product that is given only in certified healthcare settings, but its prescribing information is the clearest public list of who should not receive this class of medication.

The label names three absolute contraindications:

• Aneurysmal vascular disease, meaning a bulging weakened blood vessel in the brain, chest, abdomen, or limbs, or an arteriovenous malformation
• A history of bleeding in the brain
• Hypersensitivity to ketamine, esketamine, or any ingredient in the product

The common thread in the first two is blood pressure. The label explains that these treatments raise blood pressure for a few hours after a dose, which is dangerous when a blood vessel is already weakened.

Which medical conditions can rule someone out?

Beyond the absolute contraindications, several conditions call for a careful look and sometimes a firm no.

Blood pressure and heart conditions. According to the Spravato label, a reading above roughly 140/90 before dosing means the benefits and risks have to be weighed, and other cardiovascular or cerebrovascular conditions need careful assessment first.

Pregnancy and breastfeeding. The Spravato label says treatment is not recommended during pregnancy and that breastfeeding is not recommended during treatment.

Liver disease. The Spravato label says use is not recommended in severe hepatic impairment, and moderate impairment may require longer monitoring.

Interacting medications. Benzodiazepines, opioids, and alcohol can deepen sedation, while stimulants and MAOIs can add to the blood pressure effect. A full medication review is part of every screening.

Which psychiatric factors can rule someone out?

Psychosis. Ketamine can cause dissociation and altered perception. For that reason, the Spravato label says anyone with psychosis needs careful assessment, and treatment should begin only if the benefit clearly outweighs the risk.

Substance use history. Ketamine is a Schedule III controlled substance. Per the Spravato label, people with a history of substance use disorder face a higher risk of misuse, so treatment calls for careful consideration and monitoring. Active substance use is a common reason a provider declines to prescribe.

Bipolar disorder and mania. This is the area where it pays to be precise. A 2023 systematic review in Therapeutic Advances in Psychopharmacology pooled eight studies and found hypomanic or manic symptoms in about 2 percent of participants. In those studies, ketamine was given as an add-on to a mood stabilizer. So a bipolar diagnosis is not an automatic exclusion, but it does require an individual assessment of mood stability and current medications. Active mania or untreated bipolar disorder is something a clinician would weigh very carefully.

Why does a clinical assessment come first?

Screening exists because many of the factors above can't be seen from the outside. Nobody can tell by looking whether you have an undiagnosed vascular problem or an undisclosed substance history.

An American Psychiatric Association task force laid out what a proper evaluation includes in its consensus statement on ketamine for mood disorders. The recommended components include:

• A comprehensive diagnostic assessment, including history of substance use and psychotic disorders
• A thorough review of past treatment, current medications, and allergies, including any opiate or benzodiazepine use
• A review of medical and psychiatric records, or corroboration from family where possible
• A urine toxicology screen, which the statement strongly encourages
• An informed consent process that explains the risks and the limits of the evidence

The same statement notes that the strongest evidence is in major depression without psychotic features. People outside that group have less research behind them, which is one more reason to look at each case individually.

What happens if you are screened out?

Being screened out is not a judgment about you or your suffering. It means the risks of this treatment, in this setting, outweigh the likely benefit. Depending on the reason, a clinician may be able to point you toward other options, such as a different medication, therapy, or treatment in a supervised clinical setting.

If you are unsure where you stand, our facilitators can also help you determine if it's right for you. Contact us for more information. We offer at-home ketamine therapy in Colorado, Ohio, and Florida.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Ketamine is not FDA approved for the treatment of any psychiatric condition. Always consult a licensed healthcare provider about your medical history and any medication.